It’s not your imagination:
is issuing fewer enforcement letters to companies over drug promotions in 2016
than in previous years.
There “are not a lot of
enforcement letters so far this year,” Thomas Abrams, director
of the Food and Drug Administration's Office of Prescription Drug Promotion
a Food and Drug Law Institute conference in Washington.
But the decrease in letters doesn’t mean companies can afford to stop monitoring their drug marketing campaigns.
Indeed, Abrams stressed that the decrease in
s of letters being issued doesn't mean
a lower level of enforcement on the agency's part.
Warning and untitled letters are “just one
component of our multi
faceted approach to achieve the
objective of having nonmisleading, truthful and
balanced promotion,” Abrams said. Other facets include developing guidance
documents, reviewing draft product labeling and reviewing core launch
“We will work on issuing guidances on promotional issues,” he said, with the goal of achieving voluntary compliance.
As of Oct. 3, the OPDP had issued only four
enforcement letters in 2016 for drug marketing violations (14 PLIR 1314, 9/23/16). Three of those were untitled letters and
one was a warning letter. In 2015, OPDP issued
The OPDP issues warning letters and untitled letters to companies for drug marketing that doesn't meet the truthful, balanced and not-misleading promotional standard. An untitled letter cites violations that don't meet the threshold of regulatory significance for a warning letter, according to the agency's regulatory procedures manual. Such letters often are used for drug promotion violations.
Stay on top of new developments in health law and regulation with a free trial to the Health Law Resource Center.
Learn more about Bloomberg Law and sign up for a free trial.
Notify me when updates are available (No standing order will be created).
Put me on standing order
Notify me when new releases are available (no standing order will be created)